Balance is key
Could these medications help with conditions like MCAS (Mast Cell Activation Syndrome), fatigue, and even neurodegenerative diseases
Critically, this benefit was not solely dependent on the amount of weight lost
[DOI] [PMC free article] [PubMed] [Google Scholar] 200.Shats I., Williams J.G., Liu J., Makarov M.V., Wu X., Lih F.B., Deterding L.J., Lim C., Xu X., Randall T.A., et al
Conclusions GLP-1RA medications have progressed beyond another tool for clinicians to manage type 2 diabetes, overweight, and obesity to therapies with robust cardiovascular outcomes
The country's expanding middle class demonstrates willingness to pay for effective obesity treatment through private healthcare channels and international prescription services